New Haven drug developer Achillion Pharmaceuticals Inc. said Thursday its loss widened in the third quarter from a year ago as its cash continues to pour into clinical trials of treatments blood-borne diseases.
Achillion lost $7.2 million, or 15 cents a share, in the three months ended Sept. 30, up from its loss of $6.4 million, or 24 cents a share, the same period in 2009.
Achillion is in clinical testing of various compounds to treat chronic hepatitis C and HIV.
Counting a $50 million equity infusion earlier this year, the company said it had $62.2 million in cash and marketable securities on hand as of Sept. 30.
